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absorption. Thus, Cl
Ϫ absorption was measured in CCDs perfused in vitro that were taken from mice given aldosterone for 7 days. In wild-type mice, we observed no effect of luminal hydrochlorothiazide on either Cl Ϫ absorption or transepithelial voltage (VT). However, application of an ENaC inhibitor [benzamil (3 M) ] to the luminal fluid or application of a Na ϩ -K ϩ -ATPase inhibitor to the bath reduced Cl Ϫ absorption by ϳ66 -75% and nearly obliterated lumen-negative VT. In contrast, ENaC inhibition had no effect in CCDs from collecting duct-specific ENaC-null mice (Hoxb7:CRE, Scnn1a loxlox ). Whereas benzamil-sensitive Cl Ϫ absorption did not depend on CFTR, application of a Na ϩ -K ϩ -2Cl Ϫ cotransport inhibitor (bumetanide) to the bath or ablation of the gene encoding Na ϩ -K ϩ -2Cl Ϫ cotransporter 1 (NKCC1) blunted benzamil-sensitive Cl Ϫ absorption, although the benzamil-sensitive component of VT was unaffected. In conclusion, first, in CCDs from aldosterone-treated mice, most Cl Ϫ absorption is benzamil sensitive, whereas thiazide-sensitive Cl Ϫ absorption is undetectable. Second, benzamil-sensitive Cl Ϫ absorption occurs by inhibition of ENaC, possibly due to elimination of lumen-negative VT. Finally, benzamil-sensitive Cl Ϫ flux occurs, at least in part, through transcellular transport through a pathway that depends on NKCC1.
epithelial sodium channel; plendrin; chloride; amiloride AMILORIDE AND THIAZIDE ANALOGS have been used as antihypertensives for many years. Thiazide analogs inhibit an electroneutral NaCl cotransporter, encoded by Slc12a3, which localizes to the distal convoluted tubule (18) . However, Terada and Knepper (39) observed that thiazides inhibit transporters other than the NaCl cotransporter, since they reduce NaCl absorption in the cortical collecting duct (CCD), although the NaCl cotransporter is not expressed in that segment (18) . More recently, Leviel et al. (26) demonstrated that thiazides inhibit Na ϩ and Cl Ϫ absorption in the mouse CCD by inhibiting an electroneutral Na ϩ -dependent, Cl Ϫ /HCO 3 Ϫ exchanger encoded by Slc4a8.
The relative contribution of the thiazide-sensitive and amiloride-sensitive components of Cl Ϫ absorption have varied between studies. In CCDs from NaCl-restricted mice, virtually all Cl Ϫ absorption is thiazide sensitive, whereas amiloride-sensitive Cl Ϫ absorption is undetectable (26) . However, in DOCA-treated rats, ϳ50% of Cl Ϫ absorption is thiazide sensitive, whereas the other ϳ50% is amiloride sensitive (39) . Differences in the relative contribution of the thiazide-and amiloride-sensitive components of Cl Ϫ absorption may reflect species-or strain-specific differences. Alternatively, the expression and function of diureticsensitive transporters may differ after dietary NaCl restriction and aldosterone analog administration. If so, the relative action of these two diuretics might differ significantly in these two treatment models.
Amiloride analogs induce natriuresis by inhibiting the epithelial Na ϩ channel (ENaC), which localizes to the apical regions of principal cells (17) . Since ENaC does not transport Cl Ϫ , the mechanism of the amiloride-sensitive component of Cl Ϫ absorption is unresolved. ENaC-mediated Na ϩ absorption generates a lumen-negative transepithelial voltage (V T ), which should enhance the driving force for Cl Ϫ uptake through paracellular transport. However, other mechanisms are possible. Since the CCD is generally thought to be a "tight epithelium," amiloride may alter transcellular rather than paracellular Cl Ϫ absorption. Moreover, since apical plasma membrane Cl Ϫ channels have been reported in rabbit intercalated cells (8, 27) , eliminating the lumennegative V T generated by ENaC should enhance the driving force for Cl Ϫ secretion mediated by such an apical anion channel. Finally, amiloride analogs may target Na ϩ transporters other than ENaC. For example, Na ϩ -HCO 3 Ϫ cotransporter 3 (NBC3) is amiloride sensitive (34, 47) and localizes to the apical regions of intercalated cells in the rat (25) and mouse (21) CCD. Therefore, amiloride might directly inhibit NBC3 in intercalated cells, which reduces NaHCO 3 uptake across the apical plasma membrane, thereby attenuating apical Cl Ϫ /HCO 3 Ϫ exchange due to reduced intracellular HCO 3 Ϫ concentration. To resolve these issues, the goals of this study were to 1) determine the relative contribution of the amiloride-and thiazide-sensitive components of Cl
METHODS

Animals and Treatments
Unless otherwise indicated, experiments were performed on male and female wild-type mice on a 129S6/SvEv Tac background (Taconic Farms). We studied Na ϩ -K ϩ -2Cl Ϫ cotransporter 1 (NKCC1)-null mice on a FVB/N background, which were produced by breeding NKCC1 heterozygotes as previously described (7) . Collecting ductspecific ␣-subunit ENaC-null mice (Hoxb7:CRE, Scnn1a loxlox ) were compared with CRE-negative littermates (37) , which were on a 129B6 background. The following three treatments were performed. Treatment 1. Mice received aldosterone by minipump (250 g·kg body wt Ϫ1 ·day Ϫ1 ) and ate a balanced diet (no. 53881300, Zeigler Brothers) prepared as a gel (0.6% agar, 74.6% water, and 24.8% mouse chow) supplemented with NaCl (ϳ0.8 meq NaCl/day) for 5-7 days before euthanization (19) .
Treatment 2. Mice received a gelled diet (0.8 meq/day NaCl) and received vehicle by minipump.
Treatment 3. Mice ate the same gelled diet but supplemented with NaCl to receive 1.25 meq/day NaCl. In these experiments, mice did not receive minipumps or aldosterone.
The Institutional Animal Care and Use Committee of Emory University approved all treatment protocols.
In Vitro Perfusion of Isolated CCDs
CCDs were dissected from medullary rays and perfused at flow rates of 2-3 nl/min in the presence of a symmetric HCO 3 Ϫ -buffered physiological solution, which contained (in mM) 125 NaCl, 2.5 K 2HPO4, 24 NaHCO3, 2 CaCl2, 1.2 MgSO4, and 5.5 glucose bubbled with 95% air-5% CO2 (36) . Unless otherwise stated, ANG II (10 nM) was present in the bath solution in all experiments (31, 32) . Tubules were equilibrated at 37°C for 30 min before the collections were started. A stock solution of benzamil hydrochloride (3 ϫ 10 
Measurement of Net Transepithelial Cl Ϫ Flux
Cl Ϫ concentrations were measured in the perfusate and collected samples using a continuous-flow fluorimeter and the Cl Ϫ -sensitive fluorophore 6-methoxy-N-(3-sulfopropyl)quinolinium (Molecular Probes, Eugene, OR), as previously described (9, 42, 43) . Transepithelial Cl Ϫ flux (JCl) was calculated according to the following equation: JCl ϭ (CO Ϫ CL)Q/L, where CO and CL are perfusate and collected fluid Cl Ϫ concentrations, respectively, Q is the flow rate (in nl/min), and L is the tubule length. Net fluid transport was taken to be zero since net fluid flux has not been observed in CCDs when perfused in vitro in the presence of symmetric solutions and in the absence of vasopressin (22, 23) . J Cl was expressed as picomoles per millmeter per minuter.
Transepithelial Voltage
Transepithelial voltage (VT) was measured in the perfusion pipette connected to a high-impedance electrometer through an agar bridge saturated with 0.16 M NaCl and a calomel cell, as previously described (41) . The reference was an agar bridge from the bath to a calomel cell.
Immunohistochemistry
Kidneys were preserved by in vivo perfusion fixation and embedded in paraffin as previously described (20) . We used an NKCC1 antibody (␣-wNT) raised in rabbits against a 6xHis fusion protein corresponding to amino acids 3-202 of the rat NKCC1 sequence (5), which was a generous gift from Dr. R. James Turner. NKCC1 immunoreactivity was detected using immunoperoxidase procedures; blocking was done with 3% H 2O2 in methanol for 30 min followed by protein blocking using 1% BSA, 0.2% gelatin, and 0.05% saponin solution. The anti-NKCC1 antibody was diluted 1:3,000 in PBS, and the secondary antibody was peroxidase-conjugated goat anti-rabbit IgG (DAKO). For double-labeling experiments, NKCC1 immunostaining was performed as described above and then labeled for both aquaporin 2 (AQP2; 1:1,000) (3) and pendrin (1:5,000) (36) . In other experiments, NKCC1 labeling was followed by H ϩ -ATPase labeling (1:500) (21) . Sections that labeled NKCC1, as visualized by diaminobenzidine staining, were washed with distilled water and incubated in 0.5% H 2O2 in absolute methanol for 30 min at room temperature to quench the remaining peroxidase activity. Sections were washed with distilled water and incubated in PBS supplemented with 1% BSA, 0.05% saponin, and 0.2% gelatin followed by an overnight incubation at 4°C with primary antibodies against H ϩ -ATPase or against both AQP2 and pendrin. Sections were rinsed with PBS supplemented with 0.1% BSA, 0.05% saponin, and 0.2% gelatin, and labeling was visualized with horseradish peroxide-conjugated goat anti-rabbit secondary antibody (1:200, DAKO). For the detection of immunoreactivity, Vector SG (Vector laboratories) was used as the chromogen to produce a blue-gray label, which can be distinguished from the brown staining produced by diaminobenzidine, which labeled NKCC1.
Statistics
All data are presented as means Ϯ SE. Each n value used in the statistical analysis represents data from separate mice. To test for statistical significance between two groups, a paired or an unpaired Student's t-test was used. The criterion for statistical significance was P Ͻ 0.05.
RESULTS
Benzamil Abolishes Cl Ϫ Absorption in the CCD of Aldosterone-Treated Mice
The magnitude of the thiazide-and amiloride-sensitive components of J Cl and V T were measured in the CCD of aldosterone-treated mice (treatment 1). ANG II was applied to the perfusate to upregulate ENaC (33), pendrin (31) , and H ϩ -ATPase (32) in the CCD. To examine the contribution of the Na ϩ -dependent Cl Ϫ /HCO 3 Ϫ exchanger Slc4a8, Cl Ϫ absorption was measured before and after the application of hydrochlorothiazide to the luminal fluid (26) . As shown in Fig. 1 , 100 M hydrochlorothiazide had no measurable effect on either V T or J Cl . Further experiments explored the effect of ENaC inhibition on Cl Ϫ absorption. Since benzamil is thought to be a more selective inhibitor of ENaC than amiloride (1), we studied the effect of benzamil (3 M) on J Cl and V T (Fig. 2) . In contrast to thiazides, benzamil application reduced Cl Ϫ absorption by ϳ66% and reduced lumen-negative V T by ϳ75%. We conclude that in the CCD of aldosterone-treated mice, Cl Ϫ absorption occurs predominantly through a benzamil-sensitive, thiazide-insensitive pathway.
Benzamil Reduces Cl Ϫ Absorption by Inhibiting ENaC, Most Likely by Eliminating Lumen-Negative V T
We hypothesized that if benzamil reduces Cl Ϫ absorption by inhibiting ENaC, then inhibiting ENaC by raising the intracellular Na ϩ concentration through Na ϩ pump blockade (38) should mimic the effect of benzamil on J Cl and V T . Thus, we examined the effect of the Na ϩ -K ϩ -ATPase inhibitor ouabain on J Cl and V T (Fig. 3) . Ouabain reduced J Cl by Ͼ75% and obliterated lumen-negative V T . Therefore, benzamil and ouabain may inhibit a common pathway for Cl Ϫ absorption, which likely involves elimination of lumen-negative V T generated by ENaC.
Benzamil may reduce Cl Ϫ absorption by directly inhibiting a transporter other than ENaC, such as NBC3, or another transport process coupled with Na ϩ -K ϩ -ATPase (34, 47) . We hypothesized that if benzamil reduces J Cl through an ENaC-dependent pathway, then the benzamil-sensitive component of Cl Ϫ absorption should be abolished in ENaC-null mice. To test this hypothesis, we examined the effect of benzamil on J Cl and V T in collecting duct-specific ENaCnull mice (Hoxb7:CRE, Scnn1a loxlox ) and in wild-type, CRE-negative littermates (Fig. 4) . Application of benzamil to the lumen reduced J Cl and V T in wild-type, CRE-negative mice but had no detectable effect on J Cl and V T in collecting duct-specific ENaC-null mice. Moreover, in collecting ductspecific ENaC-null mice, the effect of benzamil (Fig. 4B ) was no different from that of vehicle (Fig. 4C) . We conclude that benzamil reduces J Cl through a mechanism that is dependent on ENaC.
Benzamil Increases Cl
Ϫ Secretion in the Mouse CCD Under physiological conditions, the lumen-negative V T generated by ENaC drives electrogenic Cl Ϫ absorption (2). However, in cultured mouse CCD monolayers, conductive Cl Ϫ secretion is observed when V T is clamped to zero ("short circuit" conditions) (2, 30) . Since the application of amiloride analogs reduces V T to nearly zero in CCDs perfused in vitro, amiloride effectively creates a short circuit condition in the perfused CCD. Therefore, we hypothesized that these diuretics increase the driving force for a conductive, Cl Ϫ secretory pathway or reduce the driving force for conductive Cl Ϫ absorption. To test this hypothesis, Cl Ϫ flux was measured in CCDs taken from mice that received a high-NaCl diet alone, without aldosterone administration in vivo or ANG II administration in vitro. Under these conditions, endogenous aldosterone and ANG II production should be low and transporters, such as pendrin, that mediate net Cl Ϫ absorption are downregulated (31, 40, 43) . As shown in Fig. 5 , in the absence of a diuretic, net Cl Ϫ flux was very low. However, with the application of benzamil to the perfusate, net Cl Ϫ secretion was observed. We conclude that benzamil application unmasks net Cl Ϫ secretion under some treatment conditions.
NKCC1 Localizes to the Basolateral Regions of Type A Intercalated Cells in the Mouse CCD
During short circuit conditions, cultured CCD cells secrete Cl Ϫ through NKCC1-mediated Cl Ϫ uptake across the basolateral membrane, which acts in series with CFTR-mediated Cl Ϫ secretion across the apical plasma membrane (2, 30) . Since NKCC1 mRNA is expressed in the mouse CCD (13) and since NKCC1 protein is expressed in the basolateral regions in principal and intercalated cells in the rabbit CCD (28), we asked if NKCC1 protein is also expressed in the mouse CCD and if NKCC1 modulates transepithelial Cl Ϫ transport in that segment. Figure 6 shows NKCC1 labeling in cortical sections taken from mice that received aldosterone or vehicle. Under basal conditions, no NKCC1 labeling was detected in the CCD. However, in cortical sections from aldosterone-treated mice, NKCC1 was observed in the basolateral regions of a minority cell type. Similarly, NKCC1 labeling was observed in the basolateral regions of a minority cell type in the outer medullary collecting duct (OMCD) of aldosterone-treated mice but not from vehicle-treated mice (Fig. 7) . We conclude that NKCC1 protein can be detected in intercalated cells in CCDs and OMCDs from aldosterone-treated mice but not from vehicle-treated mice.
Further experiments explored which cell type expresses NKCC1 in the mouse OMCD and CCD. To do so, we used H ϩ -ATPase as a marker of all intercalated cell subtypes, whereas pendrin was used as a marker of type B and non-A, non-B intercalated cells. AQP2 was used as a marker of principal cells. As shown in Fig. 8, A and B , in both the CCD and OMCD, cells that express NKCC1 do not express either AQP2 or pendrin. Thus, NKCC1 is not expressed in principal cells or in type B or non-A, non-B intercalated cells. In the mouse CCD and OMCD, the only cell type that is both pendrin and AQP2 negative is the type A intercalated cell. Therefore, we hypothesized that NKCC1 is expressed in type A intercalated cells. If so, NKCC1-positive cells should also be H ϩ -ATPase positive. As shown in Fig. 8C , in the mouse OMCD, H ϩ -ATPase labeling was detected in all cells that express NKCC1, consistent with NKCC1 expression in type A intercalated cells. We conclude that NKCC1 is expressed in the basolateral regions of type A intercalated cells in the mouse CCD and OMCD. 
Benzamil-Sensitive Cl Ϫ Secretion Is Dependent on NKCC1
The OMCD of aldosterone-treated rats (42) secretes Cl Ϫ through transepithelial transport across type A intercalated cells, by way of Cl Ϫ uptake across the basolateral membrane through NKCC1. Since NKCC1 also localizes to the basolateral regions of type A cells in the mouse CCD, we asked if transepithelial Cl Ϫ transport occurs through an NKCC1-dependent pathway and if NKCC1 inhibitors modulate ENaC-dependent Cl Ϫ transport. We hypothesized that type A intercalated cells mediate Cl Ϫ secretion through NKCC1-mediated Cl Ϫ uptake across the basolateral plasma membrane (Fig. 9) , similar to the rat OMCD (30, 42) . We further hypothesized that amiloride analogs stimulate this Cl Ϫ secretory pathway. To examine the role of NKCC1 in transepithelial Cl Ϫ transport, Cl Ϫ absorption was measured in CCDs perfused in the presence and absence of an NKCC1 inhibitor [bumetanide (100 M)] in the bath solution (Fig. 10A) (42, 45) . In the absence of benzamil, inhibition of NKCC1 had no effect on either J Cl or V T . However, with benzamil present in the perfusate (Fig. 10B) , J Cl more than doubled with bumetanide application to the bath, although V T was unaffected. Therefore, after ENaC blockade, bumetanide most likely alters Cl Ϫ flux by inhibiting Cl Ϫ secretion across type A intercalated cells.
Further experiments tested whether chemical inhibitors of NKCC1 (bumetanide) blunt the benzamil-sensitive component of Cl Ϫ absorption (Fig. 11) . To answer this question, we measured the benzamil-sensitive change in J Cl and V T when bumetanide was applied to the bath. Benzamil reduced Cl Ϫ absorption and V T in the presence as well as in the absence of bumetanide. We reasoned that chemical inhibitors of NKCC1 blunt, but do not eliminate, the benzamil-sensitive component of J Cl . Figure 12A shows that benzamil-sensitive J Cl might be reduced with bumetanide application (P ϭ 0.057), although bumetanide did not attenuate benzamil-sensitive V T (Fig. 12B) . Most notably, the ratio of benzamil-sensitive Cl Ϫ absorption relative to benzamil-sensitive V T was lower in CCDs with bumetanide present in the bath relative to vehicle-treated tubules (Fig. 12C) .
The role of NKCC1 in the benzamil-sensitive transepithelial transport of Cl Ϫ was explored further by testing the effect of benzamil on Cl Ϫ absorption in aldosterone-treated NKCC1-null mice (Fig. 13) . In these mutant mice, benzamil produced a substantial fall in V T and decreased Cl Ϫ absorption in four of five tubules studied. However, in the five tubules studied collectively, benzamil did not produce a statistically significant change in Cl Ϫ absorption. In NKCC1-null mice, the benzamil-sensitive component of J Cl was 16.0 Ϯ 10.2 pmol·mm Ϫ1 ·min Ϫ1 , which compares with 24.1 Ϯ 3.9 pmol·mm Ϫ1 ·min Ϫ1 measured in CCDs from wild-type mice in the absence of bumetanide.
In conclusion, the benzamil-sensitive component of Cl CCD. Thus, the benzamil-sensitive component of transepithelial Cl Ϫ transport occurs, at least in part, through an NKCC1-dependent pathway.
Conductive Cl Ϫ Secretion Does Not Occur Through CFTR
In cultured mouse CCD cells, Cl Ϫ secretion is accomplished through conductive Cl Ϫ secretion across the apical plasma membrane mediated by CFTR (30) . Since CFTR-mediated Cl Ϫ channels have been observed in the native mouse CCD and in cultured mouse CCD cells (29, 30) , we asked if CFTR modulates Cl Ϫ flux either in the presence or absence of benzamil in the luminal fluid. We hypothesized that if benzamil stimulates CFTR-mediated Cl Ϫ secretion, then inhibiting CFTR should increase Cl Ϫ absorption. To test this hypothesis, CCDs were perfused with benzamil present in the luminal fluid. Cl Ϫ flux was then measured before and after the application of a CFTR inhibitor (CFTR inh 172). As shown in Fig. 14 with CFTR inh 172, n ϭ 2). We conclude that CFTR does not represent a major pathway for Cl Ϫ transport in the CCD of aldosterone-treated mice. Thus, conductive apical Cl Ϫ secretion in the mouse CCD occurs through a pathway other than CFTR.
DISCUSSION
While amiloride has been available as an antihypertensive for many years, its current clinical use is limited since it is thought to be a mild diuretic. In patients with essential hypertension without hyperaldosteronism, 40 mg amiloride given once a day reduces systolic blood pressure by ϳ 12 mmHg (24) . However, in patients with hypertension due to primary hyperaldosteronism, the same dose of amiloride reduces systolic blood pressure by [33] [34] [35] [36] [37] [38] [39] [40] 24) . Therefore, amiloride is probably a more effective antihypertensive in high than in low aldosterone states (10) and is still used for the medical management of hypertension in primary aldosteronism (35) . The utility of amiloride in the treatment of the hypertension observed in hyperaldosteronism is likely due to the upregulation of ENaC that follows increased aldosterone production as well as the greater amiloride-sensitive component of Cl Ϫ absorption. The present study and previous studies have demonstrated that inhibiting ENaC with amiloride analogs produces a substantial reduction in Cl Ϫ absorption in CCDs from mice given a NaCl-replete diet and an aldosterone infusion, which could be considered to be a treatment model of primary hyperaldosteronism. This is in contrast to the absence of an amiloridesensitive change in Cl Ϫ absorption in CCDs taken from mice after dietary NaCl restriction (26) , where an appropriate physiological increase in aldosterone is observed. Therefore, amiloride might be a more effective antihypertensive during primary aldosteronism, due, in part, to the greater effect of ENaC on Cl Ϫ transport in this treatment model. However, the different results of these two studies may occur because in our study Cl Ϫ absorption was measured with ANG II present in the bath, whereas ANG II was absent in the study by Leviel et al. (26) .
The mechanism of benzamil-sensitive Cl Ϫ absorption has been thought to occur through paracellular Cl Ϫ transport driven by the lumen-negative V T generated by ENaC (12) . However, the present study demonstrates that benzamil-sensitive changes in Cl Ϫ absorption can be dissociated from benzamil-sensitive changes in V T since chemical inhibitors of NKCC1 or ablation of the gene encoding NKCC1 blunt benzamil-sensitive J Cl , although the benzamil-sensitive change in V T is not reduced. The weaker effect of benzamil on J Cl observed in CCDs from NKCC1-null mice does not occur because ENaC is downregulated in these mutant mice. Instead, we have previously observed that ENaC subunit abundance is the same or increased in kidneys from NKCC1-null mice relative to wild-type mice (44) .
In the mouse kidney (16), NKCC1 is localized to the basolateral regions of the inner medullary collecting duct, papillary surface epithelium, the juxtaglomerular afferent arteriole, and extraglomerular mesangium. In the rabbit kidney, Liu et al. (28) observed NKCC1 labeling in the basolateral regions of both principal and intercalated cells in the CCD. However, NKCC1 labeling has not been previously reported in the mouse CCD or OMCD (16) . While the present study did not detect NKCC1 labeling in the CCD or OMCD of mice under basal conditions (i.e., after a NaCl-replete diet), we observed NKCC1 labeling in the basolateral regions of type A intercalated cells in both the CCD and OMCD after aldosterone administration. These data demonstrate that in the kidney, NKCC1 is regulated by aldosterone and are consistent with a previous study (15) in the rat aorta that observed aldosteroneinduced stimulation of NKCC1-mediated transport and consistent with a study (30) of cultured mouse CCD cells that observed increased NKCC1 mRNA after the application of aldosterone.
In the OMCD from rats given an aldosterone analog, lumenpositive V T and net Cl Ϫ secretion are observed (42) . This lumen-positive V T should enhance Cl Ϫ secretion mediated by a conductive pathway. In the rat OMCD, Cl Ϫ secretion falls by ϳ70% with the application of NKCC1 inhibitors, although V T is unchanged (42) . Therefore, Cl Ϫ secretion in this segment is dependent on NKCC1-mediated Cl Ϫ uptake across the baso- lateral plasma membrane. Since NKCC1 is also expressed in basolateral regions of type A intercalated cells in the mouse CCD, one possible explanation for these findings is that in type A cells of the mouse CCD, Cl Ϫ is taken up across the basolateral plasma membrane through NKCC1 and is then secreted through a Cl Ϫ transport pathway that localizes to the apical plasma membrane (Fig. 9) . With the application of benzamil to the luminal fluid, this Cl Ϫ secretory pathway is upregulated, which reduces the net Cl Ϫ absorption that is measured.
In the CCD, the driving force for Cl Ϫ secretion mediated by an apical plasma membrane Cl Ϫ channel should be enhanced when the lumen-negative voltage is eliminated, such as with benzamil application. While the nature of the conductive pathway on the apical plasma membrane is unknown, the present study demonstrates that CFTR is not a major mechanism of Cl Ϫ transport in the CCD of aldosterone-treated mice. However, a stilbenesensitive, apical anion conductance has been observed in intercalated cells from rabbit CCDs perfused in vitro (8) (Fig. 9 ). The cosecreted cation or counteranion that accompanies amiloride-sensitive changes in Cl Ϫ transport remains to be determined.
In conclusion, in aldosterone-treated mice, the majority of Cl Ϫ absorption occurs through a benzamil-sensitive, thiazideinsensitive pathway. Inhibition of ENaC with benzamil reduces Cl Ϫ absorption, possibly from the reduced lumen-negative voltage, which should increase conductive Cl Ϫ secretion or reduce conductive Cl Ϫ absorption. However, other signaling mechanisms are possible. Benzamil-sensitive changes in Cl Ϫ absorption cannot be fully explained by changes in paracellular Cl Ϫ absorption. Instead, benzamil-sensitive Cl Ϫ absorption occurs, in part, through transcellular transport that depends on NKCC1.
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